Trial Profile
A Randomized, Open labEled, muLticenter Trial for Safety and Efficacy of Intracoronary Adult Human Mesenchymal stEm Cells Acute Myocardial infarction
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms RELIEF
- Sponsors Pharmicell
- 21 Oct 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2023.
- 21 Oct 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Aug 2022.
- 21 Oct 2020 Planned number of patients changed from 135 to 90.